Landscapes / Companies
Guangzhou FineImmune Biotechnology Co., LTD. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 in Phase 1
Drugs
3
in active trials · 4 in all
Trials
4 active
5 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1 | 19 Dec 2026Phase 1 trial completes | |||
| Next date | 19 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Tumor Associated Lymph Node T Cell and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | 25 Apr 2027Phase 1 trial completes | |||
| Next date | 25 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Sarcoma, Lung Cancers and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Apr 2028Phase 1 trial completes | |||
| Next date | 30 Apr 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma | ||||
| Open drug page | |||||
About
- No active trial
- tumor-specific TCR-T cells
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021